RxDoctor Payments Data

Lan Quang, MD

Internal Medicine · Stockton, CANPI 1437354347

Payments from drug & device makers

$16,908in general payments, 2019–2025

Across 896 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$2K
  • Vifor Pharma, Inc.$1K
  • Novo Nordisk$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Lilly USA, LLC$949
  • plus $8K from 40 others

What the payments were for

  • Food & beverage$16,38697%
  • Education$5223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,908 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$243,035
Medicare patients
360
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan23$446,370
JardianceEmpagliflozin191$216,108
VelphoroSucroferric Oxyhydroxide54$193,667
FarxigaDapagliflozin Propanediol178$177,552
OzempicSemaglutide76$128,801
XphozahTenapanor Hcl38$127,056
VeltassaPatiromer Calcium Sorbitex74$112,035
LokelmaSodium Zirconium Cyclosilicate64$65,906
RybelsusSemaglutide25$50,080
KerendiaFinerenone38$41,611
Sevelamer Carbonate68$24,683
TradjentaLinagliptin20$21,085
ProcritEpoetin Alfa35$16,768
RayaldeeCalcifediol13$15,250
JanuviaSitagliptin Phosphate11$14,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$1,002$446,37023 claims
AstraZenecaFarxiga, Lokelma$1,994$243,458242 claims
Boehringer IngelheimJardiance, Tradjenta$810$237,193211 claims
Fresenius USA Marketing, Inc.Velphoro$777$193,66754 claims
Novo NordiskOzempic, Rybelsus$1,136$178,881101 claims
BayerKerendia$584$41,61138 claims
Johnson & JohnsonProcrit$631$16,76835 claims
OPKO Pharmaceuticals, LLCRayaldee$495$15,25013 claims
MerckJanuvia$17$14,74811 claims
ANI Pharmaceuticals, Inc.Valsartan$168$97715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →